Capital International Investors
RAPP

Capital International Investors’s Rapport Therapeutics RAPP Stock Holding History

Capital International Investors’s Portfolio RAPP Stock Details RAPP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$122M Sell
2,921,958
-176,015
-6% -$6.47M 0.03% 276
2026
Q1 		$96.9M Sell
3,097,973
-304,556
-9% -$8.57M 0.02% 287
2025
Q4 		$103M Hold
3,402,529
– – 0.02% 293
2025
Q3 		$101M Buy
3,402,529
+800,000
+31% +$14.3M 0.02% 295
2025
Q2 		$29.6M Hold
2,602,529
– – 0.01% 373
2025
Q1 		$26.1M Hold
2,602,529
– – 0.01% 376
2024
Q4 		$46.2M Hold
2,602,529
– – 0.01% 346
2024
Q3 		$53.3M Sell
2,602,529
-2
-0% -$43 0.01% 319
2024
Q2 		$60.5M Buy
+2,602,531
New +$60.3M 0.01% 299

Other funds holding RAPP

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
TGV
TRV GP V Boston, Massachusetts $498M AUM 267.53% 1-Year Est. Return
AVM
Arch Venture Management Chicago, Illinois $1.1B AUM 356.62% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.95B AUM 773.9% 1-Year Est. Return
SI
Sofinnova Investments Menlo Park, California $1.93B AUM 134.74% 1-Year Est. Return
JJ
Johnson & Johnson New Brunswick, New Jersey $799M AUM 253.51% 1-Year Est. Return
PCH
Polar Capital Holdings London, United Kingdom $42.4B AUM 181.11% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return

Capital International Investors's RAPP Position: Q2 2026 in Review

Capital International Investors reduced its Rapport Therapeutics (RAPP) stake by 5.7% in Q2 2026, selling an estimated $6.47M and leaving 2,921,958 shares worth $122M. The position accounts for 0.03% of the portfolio, ranked #276.

Capital International Investors first reported a position in RAPP in Q2 2024 and has held it in 9 quarters since. 160 funds tracked by Wall St. Rank hold RAPP as of Q2 2026.

  • Capital International Investors held 2,921,958 shares of Rapport Therapeutics worth $122M as of Q2 2026.
  • Capital International Investors sold 176,015 Rapport Therapeutics shares in Q2 2026, an estimated $6.47M.
  • Rapport Therapeutics made up 0.03% of Capital International Investors's portfolio in Q2 2026, its #276 holding.
  • Capital International Investors first reported a position in Rapport Therapeutics in Q2 2024 and has held it in 9 quarters since.
  • 160 funds tracked by Wall St. Rank held Rapport Therapeutics as of Q2 2026.

Based on Capital International Investors's 13F filing for Q2 2026, filed 12 Aug 2026.